Epizyme's IPO

Epizyme raised a round of funding on May 31, 2013. Investors include Public.

Epizyme (NASDAQ: EPZM) is a biopharmaceutical company committed to rewriting treatment for cancer and other serious diseases through epigenetic medicines. Epizyme is broadly developing its lead produc…

Articles about Epizyme's IPO: